Free Trial
NASDAQ:PBLA

Panbela Therapeutics (PBLA) Stock Price, News & Analysis

Panbela Therapeutics logo
$0.26 -0.01 (-4.99%)
As of 02:03 PM Eastern

About Panbela Therapeutics Stock (NASDAQ:PBLA)

Key Stats

Today's Range
$0.20
$0.27
50-Day Range
$0.16
$0.32
52-Week Range
$0.15
$0.47
Volume
5,804 shs
Average Volume
18,248 shs
Market Capitalization
$1.25 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Hold

Company Overview

Panbela Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
7th Percentile Overall Score

PBLA MarketRank™: 

Panbela Therapeutics scored higher than 7% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Panbela Therapeutics is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Panbela Therapeutics is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Panbela Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    0.00% of the float of Panbela Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Panbela Therapeutics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Panbela Therapeutics has recently decreased by 50.00%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Panbela Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Panbela Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.00% of the float of Panbela Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Panbela Therapeutics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Panbela Therapeutics has recently decreased by 50.00%, indicating that investor sentiment is improving significantly.
  • Search Interest

    2 people have searched for PBLA on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Panbela Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 0.01% of the stock of Panbela Therapeutics is held by insiders.

  • Percentage Held by Institutions

    Only 4.37% of the stock of Panbela Therapeutics is held by institutions.

  • Read more about Panbela Therapeutics' insider trading history.
Receive PBLA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Panbela Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

PBLA Stock News Headlines

Panbela Therapeutics Announces Q3 2024 Financial Results
I was wrong about Trump
I made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his advisors, I believed him. I believed the promise that he would finally confront the single most dangerous threat to American life. That he would fix the ticking time bomb I’ve been warning about for 15 years. But I was wrong.
See More Headlines

PBLA Stock Analysis - Frequently Asked Questions

Panbela Therapeutics' stock was trading at $0.38 at the start of the year. Since then, PBLA shares have decreased by 32.4% and is now trading at $0.2570.

Panbela Therapeutics, Inc. (NASDAQ:PBLA) announced its quarterly earnings results on Thursday, August, 10th. The company reported ($159.00) earnings per share for the quarter, missing analysts' consensus estimates of ($94.20) by $64.80.

Panbela Therapeutics shares reverse split on Thursday, January 18th 2024.The 1-20 reverse split was announced on Thursday, January 18th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, January 18th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Shares of PBLA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Panbela Therapeutics investors own include Tesla (TSLA), Recursion Pharmaceuticals (RXRX), Aridis Pharmaceuticals (ARDS), Pacific Biosciences of California (PACB), Ginkgo Bioworks (DNA), Tilray Brands (TLRY) and Agnico Eagle Mines (AEM).

Company Calendar

Last Earnings
8/10/2023
Today
7/11/2025
Next Earnings (Estimated)
7/14/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:PBLA
CIK
1029125
Fax
N/A
Employees
6
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($71.13)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$25.26 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
-302.61%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.26
Quick Ratio
0.26

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($18.37) per share
Price / Book
-0.01

Miscellaneous

Outstanding Shares
4,855,000
Free Float
4,855,000
Market Cap
$1.07 million
Optionable
Not Optionable
Beta
1.34
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (NASDAQ:PBLA) was last updated on 7/11/2025 by MarketBeat.com Staff
From Our Partners